Cellectis
Develops allogeneic, or 'off-the-shelf', CAR T-cell immunotherapies for cancer.
ALCLS | PA
Overview
Corporate Details
- ISIN(s):
- FR0010425595 (+2 more)
- LEI:
- 5493000KKX5VQ37Q2W83
- Country:
- France
- Address:
- 8 RUE DE LA CROIX JARRY, 75013 PARIS
- Website:
- https://cellectis.com/en
- Sector:
- Manufacturing
Description
Cellectis is a clinical-stage biopharmaceutical company specializing in the development of immunotherapies to treat cancer. The company leverages its proprietary gene-editing platform, TALEN®, to engineer Chimeric Antigen Receptor (CAR) T-cells. Its primary focus is on creating allogeneic, or 'off-the-shelf', CAR T-cell product candidates. These therapies are derived from T-cells from healthy donors and are designed to be broadly available for a large number of patients, in contrast to autologous therapies custom-made for each individual. The TALEN® technology is used to address key challenges in allogeneic cell therapy, including preventing Graft-versus-Host Disease and mitigating rejection by the patient's immune system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2022-12-16 22:30 |
Monthly information on share capital and company voting rights
|
English | 76.5 KB | ||
| 2022-12-13 13:30 |
Cellectis annonce des données cliniques préliminaires positives pour UCART22 da…
|
French | 378.9 KB | ||
| 2022-12-13 13:30 |
Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and U…
|
English | 345.2 KB | ||
| 2022-12-01 22:41 |
Cellectis organise un webcast en direct le 13 décembre 2022
|
French | 53.3 KB | ||
| 2022-12-01 22:40 |
Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2…
|
English | 54.6 KB | ||
| 2022-11-10 15:05 |
Cellectis présente des données précliniques sur des cellules « smart » CAR T éd…
|
French | 76.7 KB | ||
| 2022-11-10 15:05 |
Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcom…
|
English | 104.2 KB | ||
| 2022-11-10 08:48 |
Cellectis publie un article dans Frontiers Bioengineering and Biotechnology sur…
|
French | 86.0 KB | ||
| 2022-11-10 08:48 |
Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Un…
|
English | 83.8 KB | ||
| 2022-11-08 22:30 |
Information mensuelle relative au nombre total des droits de vote et d’actions …
|
French | 84.7 KB | ||
| 2022-11-08 22:30 |
Monthly information on share capital and company voting rights
|
English | 77.5 KB | ||
| 2022-11-03 21:44 |
Cellectis publie ses résultats financiers pour le troisième trimestre et pour l…
|
French | 312.0 KB | ||
| 2022-11-03 21:36 |
Cellectis Provides Business Update and Reports Financial Results for Third Quar…
|
English | 443.7 KB | ||
| 2022-11-03 21:05 |
Cellectis présentera des données cliniques sur AMELI-01 et des données préclini…
|
French | 111.2 KB | ||
| 2022-11-03 21:05 |
Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCA…
|
English | 89.0 KB |
Automate Your Workflow. Get a real-time feed of all Cellectis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cellectis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cellectis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
